Deletion of the Type II activin receptor as well as gonadotrope-specific knockdown of both SMAD4 and FOXL2 resulted in a hypogonadal hypogonadism phenotype reminiscent of the Fshb knockout [53]–[55]. Here, SMAD4 is linked to hypogonadism.